Supplementary Table. Comparison between high and low inflammatory groups defined according to PLR and NLR

	Low PLR (n=150) (n,%)	High PLR (n=117) (n,%)	p-value	Low NLR (n=156) (n,%)	High NLR (n=121) (n,%)	p-value	Low CRP (n=80) (n,%)	High CRP (n=80) (n,%)	p-value
Sex									
Female	73 (48.7)	48 (41.0)	0.213	79 (50.6)	45 (37.2)	0.026	36 (45.0)	27 (33.8)	0.145
Age (year)	64.1±11.2	65.2±11.0	0.410	64.2±11.3	65.7±11.1	0.285	65.8±12.3	65.3±11.3	0.783
Median survival time (95%CI)	29.3 [20.0-38.6]	11.8 [8.1-15.5]	<0.001	26.0 [18.8-33.2]	10.6 [5.8-15.4]	0.001	28.3 [15.0-41.6]	10.6 [8.0-13.2]	<0.001
Stage			0.720			0.902			-
IIIB	12 (8.0)	8 (6.8)		11 (7.1)	9 (7.4)		80 (100)	80 (100)	
IV	138 (92.0)	109 (93.2)		145 (92.9)	112 (92.6)		0 (0)	0 (0)	
BMI (kg/m²)	23.8±3.5	22.8±3.3	0.024	24.0±3.5	22.5±3.3	0.001	23.2±3.3	22.9±3.3	0.653
EGFR mutation	(n=147) 50 (34.0)	(n=110) 41 (37.3)	0.589	(n=151) 58 (38.4)	(n=33) 34 (29.3)	0.121	(n=76) 35 (46.1)	(n=75) 24 (32.0)	0.077
Ever smoker	68 (45.3)	54 (46.6)	0.843	70 (44.9)	57 (47.5)	0.664	35 (44.3)	43 (53.8)	0.234
ECOG			0.725			0.053			0.108
0-1	127 (84.7)	100 (86.2)		139 (89.1)	97 (80.8)		72 (91.1)	66 (82.5)	
2-3	23 (15.3)	16 (13.8)		17 (10.9)	23 (19.2)		7 (8.9)	14 (17.5)	

Pathology			0.739			0.184			0.010
Non-squamous	134 (89.3)	103 (88.0)		142 (91.0)	104 (86.0)		75 (93.8)	64 (80.0)	
Squamous	16 (10.7)	14 (12.0)		14 (9.0)	17 (14.0)		5 (6.3)	16 (20.0)	
FEV1 (liter)	2.1±1.7	1.8±0.7	0.062	2.1±1.7	1.8±0.8	0.060	2.1±2.3	1.7±0.7	0.114
FEV1 (% predicted)	80.8±21.8	77.2±22.4	0.196	81.4±21.1	75.5±23.6	0.031	78.1±20.5	65.8±17.9	<0.001
FVC (liter)	2.7±1.0	2.7±2.8	0.993	2.6±1.0	2.7±2.7	0.736	2.5±0.7	2.6±3.3	0.649
FVC (% predicted)	80.7±20.4	74.4±22.8	0.020	80.9±20.8	73.5±22.5	0.005	75.9±19.4	63.7±17.5	<0.001
FEV1/FVC(% predicted)	73.5±11.0	75.1±10.2	0.215	73.9±10.6	74.0±11.7	0.962	74.6±11.1	74.5±12.4	0.963
NLR	2.6±1.3	5.6±3.4	<0.001	2.2±0.7	6.5±4.1	0.001	3.5±2.7	5.3±4.0	0.001
PLR	130±32	266±72	<0.001	143±50	250±86	<0.001	192.5±96.0	216.8±77.7	0.091
CRP	3.56±0.68	3.66±0.52	0.915	2.37±0.52	5.11±0.63	0.001	0.51±0.48	6.97±6.03	<0.001

Abbreviations: COPD; chronic obstructive pulmonary disease, CRP; c-reactive protein, BMI; body mass index, EGFR; epidermal growth factor receptor, ECOG; Eastern Cooperative Oncology Group, FEV1; forced expiratory volume in 1 s, FVC; forced vital capacity, DLCO; diffusing capacity of the lung for carbon monoxide, HR; hazard ratio, CI; confidence interval, NLR; neutrophil-lymphocyte ratio, PLR; platelet-lymphocyte ratio

A

Non COPD, PLR low	52	43	32	23	13
Non COPD, PLR high	53	40	30	21	15
COPD, PLR low	55	42	35	25	11
COPD, PLR high	50	38	27	20	15

Number at risk

B

Number at risk					
Non-COPD, NLR low	44	44	34	24	14
Non-COPD, NLR high	34	31	24	21	11
COPD, NLR low	23	15	5	6	4
COPD, NLR high	25	18	6	5	5

C

Non-COPD, low CRP				
Non-COPD, high CRP				
COPD, low CRP				
COPD, high CRP				

Number at risk

Supplementary figure legends

Supp. Fig. 1A Comparison of progression free survival between the 4 COPD-PLR subgroups

Supp. Fig. 1B Comparison of progression free survival between the 4 COPD-NLR subgroups

Supp. Fig. 1C Comparison of progression free survival between the 4 COPD-CRP subgroups